The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
September 18th 2024
The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.
September 7th 2024
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Bariatric Surgery Dramatically Lowers Liver, Cardiovascular Risk in Patients with NASH
November 23rd 2021Undergoing bariatric surgery was associated with reductions in risk of adverse liver outcomes and MACE versus nonsurgical management among patients with obesity and biopsy-proven nonalcoholic steatohepatitis in the SPLENDOR study.
Doctors Weigh Cardiovascular Risk Reduction Over Side Effects for Antihyperglycemic Agents
The least selected attributes were food and medication restrictions and A1c lowering followed by risk of diabetic ketoacidosis, risk of genital infection, and the avoidance of severe hypoglycemia.
Endocrine Case Report: Buttock Pain
October 26th 2021Our latest emergency department quiz from Brady Pregerson, MD, features a woman in her 40’s presenting with 3 days of generalized malaise and worsening left buttock pain with subjective fevers. Check out the CT and see if you can determine the correct diagnosis.
Multidisciplinary Collaboration of Care in Diabetes and Cardiovascular Disease
October 22nd 2021A panel of experts discuss their experience with multidisciplinary collaboration of care between primary care physicians, cardiologists, endocrinologists, and pharmacists in patients with diabetes and cardiovascular disease.
Cardiovascular Disease Guidelines for Diabetes Medications
October 22nd 2021Muthiah Vaduganathan, MD, MPH, provides insight into cardiology guidelines for the use of SGLT-2 [sodium-glucose cotransporter-2] inhibitors and GLP-1 [glucagon-like peptide-1] receptor agonists and discusses the uptake of these medications in patients with and without diabetes.